“The Russian Direct Investment Fund (RDIF) has announced the approval by the Ministry of Health of the Republic of Kazakhstan of the Russian Sputnik M vaccine for adolescents aged 12-17,” the fund said in a Telegram message.
RDIF emphasized that Kazakhstan became the first foreign country to approve the use of Sputnik M.
Earlier, Deputy Head of the Ministry of Health Sergei Glagolev said that clinical trials of the Sputnik M coronavirus vaccine for adolescents aged 12-17 were completed without any serious adverse reactions to the drug.